Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir PK During Weekly Rifapentine/Isoniazid for TB Prevention
NCT06281834Phase 1Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Nov 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dolutegravir and rifapentine in human immunodeficiency virus infection (HIV) and Tuberculosis (TB), sponsored by Brigham and Women's Hospital. Primary endpoint: Dolutegravir Area Under the Curve at 6 weeks. Started Nov 2024; status: recruiting.
02
Drugs
dolutegravirrifapentine
03
Conditions
human immunodeficiency virus infection (HIV)Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06281834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06281834.